AccessibilityHelp
CelLBxHealth Plc logo

CelLBxHealth Plc(LSE) AGL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-100%
5 Year-99%
1 Year-70%
1 Month-27%
N/A
CelLBxHealth Plc last closing stock price
MetricPriceDate
Last closeGBX 0.642026-10-26
CelLBxHealth Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%GBX 0.802026-10-19
1 month-26.86%GBX 0.882026-09-25
3 month-49.61%GBX 1.272026-07-28
Year to date-41.82%GBX 1.102025-12-31
1 year-69.95%GBX 2.132025-10-24
3 year-94.55%GBX 11.752023-10-27
5 year-99.48%GBX 123.502021-10-27
Since inception-99.6%GBX 1.492004-03-17

CelLBxHealth Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£2.27M

Net Income (TTM)

-£22.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Apr 23, 2026

AGL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CelLBxHealth Plc

CelLBxHealth plc is a holding company focused on cancer diagnostics and fetal health. The company specializes in innovative products, including the Parsortix cell separation system, which captures rare cells from blood.

Products and Services
  • Parsortix cell separation system for cancer diagnostics
  • Innovative solutions for fetal health monitoring
  • Research and development in medical technology
Growth Outlook
  • Recent quarterly revenue increased to £555,000, showing potential for growth
  • Cash and cash equivalents reached £7.35 million, providing operational stability
  • Focus on expanding product offerings in the healthcare sector
Financial Highlights
  • Net income for Q4 2025 was -£10.24 million, indicating ongoing investment in growth
  • Operating income ratio for Q4 2025 was -18.97%, reflecting strategic expenditures
  • Gross profit margin improved to -7.94% in Q4 2025, suggesting operational efficiencies
CelLBxHealth plc operates in the medical distribution industry, primarily focusing on cancer diagnostics and fetal health. The Parsortix system is a key product, designed to enhance the detection of rare cells, which is crucial for early cancer diagnosis. The company has shown resilience in its financial performance, with a notable increase in quarterly revenue, indicating a positive trajectory in its market presence. The growth outlook appears promising, supported by a solid cash position that allows for continued investment in research and development. The recent financial data highlights a commitment to expanding product offerings, which may enhance market competitiveness. Despite reporting a net loss, the strategic focus on innovation and operational efficiencies suggests a pathway toward future profitability. Investors may find CelLBxHealth plc an intriguing opportunity within the healthcare sector, particularly given its innovative approach to cancer diagnostics and fetal health. The company's ongoing efforts to improve its financial metrics and expand its product line could position it favorably in a rapidly evolving market.
AI Generated • Oct 8, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

44

CEO

Peter Collins

Website

www.angleplc.com

Headquarters

Guildford, RG1 8LS, GB

AGL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-224.18%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-£3.36M

Operating Income

-£28.44M

EBITDA

-£16.67M

Operating Cash Flow

-£12.56M

Capital Expenditure

-£357.00K

Free Cash Flow

-£12.92M

Cash & ST Invst.

£7.35M

Total Debt

£1.82M

CelLBxHealth Plc Performance Analysis

CelLBxHealth Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 1,041,0002.8%
20232023-12-31GBP 2,186,000110.0%
20242024-12-31GBP 2,862,00030.9%
20252025-12-31GBP 1,351,000-52.8%
CelLBxHealth Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-56.5%
Q22025-06-30N/A
Q42025-12-31N/A
CelLBxHealth Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.0931.8%
20232023-12-31GBP -0.08-12.1%
20242024-12-31GBP -0.05-37.6%
20252025-12-31GBP -0.0614.3%
CelLBxHealth Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-42.6%
Q22025-06-30N/A
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£555.00K

-39.3%

Gross Profit

-£4.41M

-854.6%

Gross Margin

-7.94%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

119

N/A

Net Income

-£10.24M

-214.5%

EBITDA

-£5.76M

-92.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£7.35M

-29.5%

Total Debt

£1.82M

-56.8%

Accounts Receivable

£1.74M

-16.4%

Inventory

£1.30M

-17.9%

Long Term Debt

£1.00M

-70.1%

Short Term Debt

£817.00K

-5.2%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-£4.76M

-37.4%

Operating Cash Flow

-£4.64M

-39.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GDR.LGenedrive Plc
£0.01-5.45%
FUM.LFutura Medical plc
£0.00+9.38%
RUA.LRUA Life Sciences plc
£0.27-0.55%
PRM.LProteome Sciences plc
£0.01-6.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
EWZiShares - iShares Msci Brazil ETF
$42.59+1.77%
NUNu Holdings
$15.16+2.92%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$52.46-1.85%

Questions About AGL

What is the current price of CelLBxHealth Plc?

CelLBxHealth Plc is trading at N/A per share.

What is the 52-week range for CelLBxHealth Plc?

Over the past 52 weeks, CelLBxHealth Plc has traded between N/A and N/A.

How much debt does CelLBxHealth Plc have?

As of the most recent reporting period, CelLBxHealth Plc reported total debt of £1.82M.

How much cash does CelLBxHealth Plc have on hand?

CelLBxHealth Plc reported £7.35M in cash and cash equivalents in its most recent financial results.

What is CelLBxHealth Plc’s dividend yield?

CelLBxHealth Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services